


# MSCI USA IMI Genomic Innovation Select 50 Index (USD)

The MSCI USA IMI Genomic Innovation Select 50 Index is based on the MSCI USA IMI Index, its parent index, and includes large, mid and small-cap securities of the U.S equity markets. The Index aims to represent the performance of a set of companies that are expected to derive significant revenues, based on the underlying index methodology criteria, from the development of new products and services in the field of genomic sequencing, synthesis, analysis or instrumentation, enable bio computing, bioinformatics, molecular diagnostics and agricultural biotechnology.

For a complete description of the index methodology, please see [Index methodology - MSCI](#).

## CUMULATIVE INDEX PERFORMANCE – NET RETURNS (USD) (NOV 2016 – MAY 2026)



## ANNUAL PERFORMANCE (%)

Year	MSCI USA IMI Genomic Innovation Select 50	MSCI USA IMI
2025	19.24	16.81
2024	-1.39	23.32
2023	0.46	25.64
2022	-31.36	-19.61
2021	2.44	25.62
2020	46.58	20.46
2019	36.48	30.39
2018	-10.32	-5.72
2017	34.08	20.59

## INDEX PERFORMANCE – NET RETURNS (%) (MAY 29, 2026)

	1 Mo	3 Mo	1 Yr	YTD	ANNUALIZED				Since Nov 30, 2016
					3 Yr	5 Yr	10 Yr	Since Nov 30, 2016	
MSCI USA IMI Genomic Innovation Select 50	7.93	0.56	34.78	-0.89	6.35	-3.56	na	6.95	
MSCI USA IMI	5.09	10.24	29.55	11.39	22.88	12.67	na	14.78	

## FUNDAMENTALS (MAY 29, 2026)

Div Yld (%)	P/E	P/E Fwd	P/BV
0.32	-467.35	136.70	5.29
1.14	28.66	21.40	5.27

## INDEX RISK AND RETURN CHARACTERISTICS (NOV 30, 2016 – MAY 29, 2026)

	Beta	Tracking Error (%)	Turnover (%) <sup>1</sup>	ANNUALIZED STD DEV (%) <sup>2</sup>			SHARPE RATIO <sup>2,3</sup>			Since Nov 30, 2016	MAXIMUM DRAWDOWN	
				3 Yr	5 Yr	10 Yr	3 Yr	5 Yr	10 Yr		(%)	Period YYYY-MM-DD
MSCI USA IMI Genomic Innovation Select 50	0.98	15.57	34.13	20.51	21.71	na	0.17	-0.22	na	0.30	53.02	2021-09-09–2023-10-30
MSCI USA IMI	1.00	0.00	1.55	13.74	16.14	na	1.24	0.61	na	0.79	35.04	2020-02-19–2020-03-23

<sup>1</sup> Last 12 months

<sup>2</sup> Based on monthly net returns data

<sup>3</sup> Based on NY FED Overnight SOFR from Sep 1 2021 & on ICE LIBOR 1M prior that date

## MSCI USA IMI Genomic Innovation Select 50 Index (USD)

### INDEX CHARACTERISTICS

	MSCI USA IMI Genomic Innovation Select 50	MSCI USA IMI
<b>Number of Constituents</b>	44	2,161
	Weight (%)	
<b>Largest</b>	7.30	7.09
<b>Smallest</b>	0.16	0.00
<b>Average</b>	2.27	0.05
<b>Median</b>	1.47	0.01

### TOP 10 CONSTITUENTS

	Index Wt. (%)	Parent Index Wt. (%)
ILLUMINA	7.30	0.03
LILLY (ELI) & COMPANY	5.94	1.23
NATERA	5.83	0.04
VERTEX PHARMACEUTICALS	5.63	0.16
GUARDANT HEALTH	5.37	0.02
MODERNA	5.05	0.02
AGILENT TECHNOLOGIES	4.89	0.05
DANAHER CORP	4.55	0.16
REVVITY	4.48	0.02
MEDPACE HOLDINGS	3.71	0.01
Total	52.75	1.75

The MSCI USA IMI Genomic Innovation Select 50 Index was launched on Jan 22, 2021. Data prior to the launch date is back-tested test (i.e. calculations of how the index might have performed over that time period had the index existed). There are frequently material differences between back-tested performance and actual results. Past performance – whether actual or back-tested – is no indication or guarantee of future performance.

## ABOUT MSCI

MSCI (NYSE: MSCI Inc.) strengthens global markets by connecting participants across the financial ecosystem with a common language. Our research-based data, analytics and indexes, supported by advanced technology, set standards for global investors and help our clients understand risks and opportunities so they can make better decisions and unlock innovation. We serve asset managers and owners, private-market sponsors and investors, hedge funds, wealth managers, banks, insurers and corporates. To learn more, please visit [www.msci.com](http://www.msci.com).

The data, data feeds, databases, reports, text, graphs, charts, images, videos, recordings, models, metrics, analytics, indexes, assessments, ratings, scores, software, websites, products, services and other information delivered in connection with this notice (the "Information"): (a) are proprietary information of MSCI and its suppliers, (b) may not be used for commercial purposes without prior written permission from MSCI Inc. or its affiliates ("MSCI"), and (c) are not investment advice and must not be relied on as such. The Information and its use are further subject to the disclaimer at <https://www.msci.com/legal/notice-and-disclaimer>. As detailed therein, MSCI AND ITS SUPPLIERS MAKE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIM ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW. For information about how MSCI collects and uses personal data, refer to <https://www.msci.com/privacy-pledge>.

© 2026 MSCI Inc. All rights reserved.

